PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

QR Code

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

BackgroundImmunotherapy plays a crucial role in the treatment of tumors. However, few studies have investigated the relationship between the expression of Programmed Cell Death Ligand 1 (PD-L1, CD274) in microvascular endothelial cells (MECs), including blood endothelial cells (BECs) and lymphatic e...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yingfang Feng, Yuan Gao, Shaochuan Liu, Tingting Qin, Yan Zhang, Jing Wang, Kai Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	anlotinib PD-L1 microvascular endothelial cells immune checkpoints melanoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1544278/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report
by: Xiaochun Chen, et al.
Published: (2025-07-01)

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
by: Charlée Nardin, et al.
Published: (2025-06-01)

Baicalin Induces IFN-α/β and IFN-γ Expressions in Cultured Mouse Pulmonary Microvascular Endothelial Cells
by: Ge HU, et al.
Published: (2012-04-01)

Effects of Polysaccharides from Pulsatilla Decoction on the Microvascular Endothelial Glycocalyx
by: Tao ZHANG, et al.
Published: (2014-11-01)

Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Chen TF, et al.
Published: (2025-06-01)

Radiotherapy combined with anlotinib for refractory leiomyosarcoma: a case report and literature review
by: Ziming Li, et al.
Published: (2025-07-01)

Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01)

Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy
by: Dweeti Nayak, et al.
Published: (2025-08-01)

PROGNOSTIC VALUE OF ENDOTHELIAL DYSFUNCTION IN CORONARY AND BRACHIAL ARTERIES, AND COMMON RISK FACTORS IN DEVELOPMENT OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH MICROVASCULAR ANGINA
by: G. N. Soboleva, et al.
Published: (2017-03-01)

Continuous Anlotinib Combined with Oral Vinorelbine has Shown Anti-Tumor Efficiency in Refractory HER2 Negative Advanced Breast Cancer
by: Huang JY, et al.
Published: (2025-06-01)

ACTOVEGIN INFLUENCE ON METABOLIC AND VASOMOTOR FUNCTION OF MICROVASCULAR ENDOTHELIAL OF HUMAN SKIN
by: A. A. Fedorovich, et al.
Published: (2016-01-01)

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer
by: Linsong Mu, et al.
Published: (2019-12-01)

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study
by: Deng T, et al.
Published: (2025-07-01)

Velogenic Newcastle disease virus invades chicken brain by infecting brain microvascular endothelial cells to increase blood-brain barrier permeability
by: Jie Zhao, et al.
Published: (2025-02-01)

Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation
by: Zhu LJ, et al.
Published: (2025-07-01)

The role of markers of endothelial dysfunction in the pathogenesis of coronary microvascular dysfunction in patients with non-obstructive coronary artery disease
by: K. V. Kopeva, et al.
Published: (2024-10-01)

Coronary Microvascular Dysfunction: Epidemiology, Clinical Presentation, Diagnosis and Treatment
by: E. L. Trisvetova
Published: (2023-05-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Evaluation of the efficacy and safety of TACE combined with anlotinib and sintilimab in the treatment of patient with CNLC stage ⅡB-ⅢB liver cancer
by: TONG Gang, HUA Yang, PENG Wei, ZHAO Ju, HU Junwen
Published: (2025-05-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study
by: Zhiyong Li, et al.
Published: (2025-12-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)

Efficacy and safety of anlotinib in combination with ¹³¹I therapy in the treatment of distant metastatic differentiated thyroid cancer: a single-arm, phase II study
by: Yan Li, et al.
Published: (2025-07-01)

Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01)

Clinical and immunological features of PD-1 and Tim-3 expression on monocytes in axial spondyloarthritis
by: Ekaterina Ya. Shevela, et al.
Published: (2019-08-01)

Establishment of an Assay with Ultrahigh Sensitivity for Detecting sEV-Derived PD-L1 as a Serum Biomarker for Lung Cancer—A Pilot Study Using TN-cyclon™
by: Kyo Okita, et al.
Published: (2025-07-01)

Expression of Vascular Endothelial Growth Factor in Uveal Melanoma
by: V. G. Likhvantseva, et al.
Published: (2021-12-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1
by: Guillermina Ferro-Flores, et al.
Published: (2025-07-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
by: Yirui Zhai, et al.
Published: (2025-08-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

CLINICAL CASE OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH MICROVASCULAR ANGINA
by: Yu. I. Minyuk, et al.
Published: (2020-03-01)

Ligand-associated activation of vitamin D receptors and potential points of application of its effects in the morphogenesis of immune inflammation: Literature review
by: E. T. Ablyakimov, et al.
Published: (2024-07-01)

Efficacy of Trimetazidine and Sulodexide in Patients with Microvascular Angina
by: S. A. Boldueva, et al.
Published: (2020-07-01)

A Chemoinformatics Investigation of Spectral and Quantum Chemistry Patterns for Discovering New Drug Leads from Natural Products Targeting the PD-1/PD-L1 Immune Checkpoint, with a Particular Focus on Naturally Occurring Marine Products
by: Henrique Rabelo, et al.
Published: (2025-06-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)